Galapagos Enters into Oncology Target Discovery Collaboration with Janssen Pharmaceutica
News Jan 04, 2008
BioFocus DPI will apply Galapagos’ proprietary adenoviral platform to identify drug targets for the development of cancer therapies.
The goal of the new collaboration will be to discover and validate novel targets in the field of oncology. BioFocus DPI will perform assay development, screening of the SilenceSelect® and FLeXSelect® adenoviral libraries, and target validation. Target discovery in in-vitro assays may provide drug targets for cancer areas with an unmet medical need.
BioFocus DPI receives an upfront payment of €2.9 million. In total, BioFocus DPI may receive additional research, acceptance, license and development fees of up to €7.6 million should certain predetermined criteria be achieved.
“This marks BioFocus DPI’s first target discovery agreement in oncology, as well as the largest target discovery agreement to date for the service division,” said Onno van de Stolpe, Chief Executive Officer of Galapagos.
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE